Navigation Links
American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA

Study highlights:

- A new anti-clotting drug proved as effective as the blood thinner currently used to prevent stroke in atrial fibrillation patients with prior stroke or transient ischemic attacks

- The lower dose of the drug dabigatran produced less risk of bleeding in the brain than warfarin did

- Dabigatran is not approved in the United States but is available in other countries to prevent blood clots after elective hip and knee replacement surgery

SAN ANTONIO, Feb. 26 /PRNewswire-USNewswire/ -- The drug dabigatran was as effective as the currently recommended drug – warfarin – in preventing a subsequent stroke among people with atrial fibrillation and prior stroke or transient ischemic attack – and it did so with less bleeding according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

(Logo: )

Dabigatran is a member of a new class of anti-clotting drugs called direct thrombin inhibitors.

The findings come from a subset of patients who participated in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial, which tested the efficacy of the two drugs in people with irregular heart rhythm called atrial fibrillation.  Researchers enrolled RE-LY participants at 951 sites in 44 countries, including the United States.  They randomized patients to receive warfarin —adjusted to maintain the drug's therapeutic range — or to 110 mg or 150 mg of dabigatran taken twice daily for a median of two years.

In the subgroup of 3,623 patients with both a history of either stroke or transient ischemic attack (TIA), stroke or clot in other blood vessels occurred in 64 patients on warfarin (2.74 percent a year), 55 on low-dose dabigatran (2.32 percent a year) and 51 on high-dose dabigatran (2.07 percent a year).  

Neither of these differences was significant.

The rates of major bleeding events were significantly lower (32 percent less likely) in patients taking the lower dose of dabigatran compared to those taking warfarin, but it was not reduced in patients on the higher dose.

The risk of cerebral bleeds was significantly reduced with both dosages of dabigatran.  Researchers also noted that dabigatran-treated patients suffered more heart attacks than the warfarin group although the absolute difference was small.

Dabigitran has not yet been approved for use in the United States.  It is approved in other countries for the primary prevention of blood clots in patients who have undergone elective total hip or elective total knee replacement surgery.

"You can prevent stroke with dabigatran, a drug that is more potent than warfarin and causes less cerebral bleeding," said lead author Hans-Christoph Diener, M.D., Ph.D., professor and chairman of neurology at University Hospital in Essen, Germany.

In the overall RELY study population the higher dose of dabigatran was also linked with higher rates of gastrointestinal bleeding, but Diener said that was of less concern. "Generally gastrointestinal bleedings can be handled, but severe intracranial bleeding with warfarin usually leads to death or permanent disability," he noted.

Warfarin has long been the recommended drug for preventing strokes in people with atrial fibrillation.  However, warfarin increases the risk of brain and gastrointestinal bleeding, and the drug is difficult to manage, Diener said.  It adversely interacts with some foods and drugs, and its therapeutic range is narrow.  Too much warfarin can cause bleeding, including in the brain, and too little can result in an ischemic stroke – caused by blood clots dislocated from the heart.  Thus, physicians must monitor patients closely.

"Dabigatran's efficacy is independent of body weight and age, there are no food interactions, and you don't have to see a physician regularly to monitor the coagulation system," he said.

The risk of stroke is increased in atrial fibrillation patients, and especially in those who have already suffered a stroke or transient ischemic attack.

Co-authors are Stuart Connolly, M. D.; Michael D. Ezekowitz, M.B., Ch.B, D.Phil.; Salim Yusuf, F.R.C.P.C., D.Phil.; Lars Wallentin, M.D., Ph.D.; Jeanne Varrone, M.D.; Susan Wang, Ph.D.;  and Paul A. Reilly, Ph.D.  Author disclosures are on the abstract.

Pharmaceutical-maker Boehringer-Ingelheim GmbH funded the trial.

Click here to view the video interview with Hans-Christopher Diener, M.D., Ph.D.

Statements and conclusions of study authors that are presented at American Heart Association/American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.  The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing science content.  Revenues from pharmaceutical and device corporations are available at

NR10- 1026 (ISC 2010/Diener)

Note: Actual Presentation time is 12:15 p.m. CT, Friday. Feb. 26, 2010.

SOURCE American Heart Association

Back to top



SOURCE American Heart Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Aspirin Named 8th World Wonder by Majority of Americans
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
8. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
9. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... University of Toronto and the University of British Columbia suggested that laws requiring bicyclists ... The article explains that part of the reason for the controversial conclusion is that, ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... ... Lizzie’s Lice Pickers just announced a special promotion that will run throughout ... of lice treatment product. In addition, customers will receive a complimentary head Check when ... is a sure way to ruin the holidays, so we encourage all of our ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community ... 30 (see Table 1-1 ). More than 3.7 billion people under the age ... type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . , ...
Breaking Medicine News(10 mins):